8-K: Ginkgo Bioworks Reports Q4 and Full Year 2024 Financial Results, Announces Restructuring Progress

Ginkgo Bioworks reports increased Q4 revenue and progress on restructuring, including improved cash flow and cost savings.

Summary

• Ginkgo Bioworks announced its Q4 and full year 2024 financial results on February 25, 2025.
• Q4 2024 total revenue increased to $44 million from $35 million in the prior year.
• Cell Engineering revenue in Q4 2024 grew by 29% to $35 million.
• Biosecurity revenue in Q4 2024 was $9 million, with a gross profit margin of 17%.
• GAAP net loss for Q4 2024 was $(108) million, an improvement from $(212) million in the prior year.
• Adjusted EBITDA for Q4 2024 was $(57) million, compared to $(101) million in the prior year.
• The company's cash and cash equivalents balance was $562 million as of December 31, 2024.
• Cash flow improved to $(55) million in Q4 2024 from $(114) million in Q3 2024.
• Full year 2024 total revenue was $227 million, down 10% from the prior year.
• Full year 2024 Cell Engineering revenue increased by 21% to $174 million.
• Full year 2024 Biosecurity revenue decreased by 51% to $53 million, with a gross profit margin of 27%.
• GAAP net loss for full year 2024 was $(547) million, compared to $(893) million in the prior year.
• Adjusted EBITDA for full year 2024 was $(293) million, compared to $(365) million in the prior year.
• Ginkgo expects total revenue of $160-$180 million in 2025.
• Ginkgo expects Cell Engineering revenue of $110-$130 million in 2025.
• Ginkgo expects Biosecurity revenue of at least $50 million in 2025.
• The company aims to reach Adjusted EBITDA breakeven by the end of 2026.
• Ginkgo has achieved an annualized run-rate cost reduction of $190 million as of Q4 2024 and targets $250 million by the end of Q3 2025.
• Site consolidation efforts have been substantially completed.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down year-over-year, there's progress in cost-cutting and improved cash flow, suggesting a turnaround strategy is underway. The forward-looking statements provide some optimism, but the company still faces challenges in achieving profitability.

Positives

• Cell Engineering revenue increased by 29% in Q4 2024.
• GAAP net loss improved in both Q4 and full year 2024 compared to the prior year.
• Adjusted EBITDA improved in both Q4 and full year 2024 compared to the prior year.
• Cash flow improved in Q4 2024 compared to Q3 2024.
• The company is making progress on its restructuring plan, including cost-cutting measures and site consolidation.
• Ginkgo is expanding into life science tools with Datapoints and Automation offerings.
• Ginkgo was awarded a contract with the European Health and Digital Executive Agency (HaDEA) to deliver next-generation agnostic diagnostics for respiratory viruses at the point of care, with Ginkgo and its consortium partners eligible to receive up to 24 million over the next 4 years.

Negatives

• Full year 2024 total revenue decreased by 10% compared to the prior year.
• Full year 2024 Biosecurity revenue decreased by 51% compared to the prior year.
• The company reported a GAAP net loss of $(547) million for the full year 2024.
• The company reported an Adjusted EBITDA loss of $(293) million for the full year 2024.

Risks

• The company's ability to realize near-term and long-term cost savings associated with its site consolidation plans is uncertain.
• Volatility in the price of Ginkgo's securities could be influenced by various factors, including changes in the competitive and regulatory landscape.
• Downturns in demand for products using synthetic biology could negatively impact the company's performance.
• Uncertainty regarding the demand for passive monitoring programs and biosecurity services exists.
• Changes to the biosecurity industry, including advancements in technology and emerging competition, could pose challenges.
• The outcome of any pending or potential legal proceedings against Ginkgo is uncertain.
• The company's ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables is not guaranteed.
• The product development, production, or manufacturing success of Ginkgo's customers is subject to risk.
• The company is exposed to the volatility and liquidity risks inherent in holding equity interests in other operating companies.
• The potential negative impact on the business of the restructuring or the failure to realize the anticipated savings associated therewith is a risk.
• Uncertainty regarding government budgetary priorities and funding allocated to government agencies could affect the company's biosecurity business.

Future Outlook

Ginkgo expects total revenue of $160-$180 million in 2025, Cell Engineering revenue of $110-$130 million, and Biosecurity revenue of at least $50 million; the company aims to reach Adjusted EBITDA breakeven by the end of 2026.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo Bioworks, stated that the team is pushing the technical envelope and delivering for customers.
• Jason Kelly mentioned that the company's expansions into life science tools are going well and they are continuing to drive cost-cutting and sustainable revenue-generating efforts.

Industry Context

Ginkgo Bioworks is positioning itself as a key player in the synthetic biology industry, focusing on cell programming and biosecurity. The company's expansion into life science tools and its efforts to secure government contracts align with broader industry trends towards leveraging synthetic biology for various applications, including healthcare and biodefense.

Comparison to Industry Standards

• Ginkgo's focus on cell engineering and biosecurity aligns with the broader synthetic biology industry, which includes companies like Amyris, Zymergen (acquired by Ginkgo), and Twist Bioscience.
• Ginkgo's revenue model, which involves providing a platform for cell programming, is similar to that of other synthetic biology companies that offer services and tools to customers in various industries.
• The company's efforts to secure government contracts in the biosecurity space are comparable to those of other companies in the industry that are working to develop solutions for biodefense and pandemic preparedness.
• Ginkgo's Adjusted EBITDA losses are not uncommon for growth-stage companies in the synthetic biology industry, which often require significant investments in research and development.

Stakeholder Impact

• Shareholders may be concerned about the decrease in full year revenue but encouraged by the improved cash flow and cost-cutting measures.
• Employees may be affected by the restructuring and cost-cutting measures, including potential job losses.
• Customers may benefit from the company's expanded offerings and improved platform.
• Suppliers may be impacted by the company's cost-cutting measures.
• Creditors may be concerned about the company's losses but reassured by its cash position.

Next Steps

• Ginkgo will host a videoconference on February 25, 2025, to discuss the financial results and business updates.
• The company will continue to focus on cost-cutting measures and site consolidation.
• Ginkgo will continue to expand its life science tools offerings.
• Ginkgo will continue to work towards creating solutions that offer persistent, pervasive monitoring of biothreats.

Key Dates